There is a significant amount of activity in the pharmaceutical industry in mobilising to meet the requirements of recent Drug Quality and Safety Act (DQSA) legislation, passed by the United States Congress with the intention of limiting the spread of counterfeit or otherwise falsified medicines to patients for prescription drug products. Justin Schroeder, Executive Director, Marketing, Business Development & Design at PCI Pharma Services (PCI), reviews serialisation from the perspective of commercial versus clinical.